Key result
Immune checkpoint inhibitors are associated with rare but potentially severe cardiovascular toxicities, most notably myocarditis, which require early detection and management.
Why the study?
Immune checkpoint inhibitors improve cancer survival but can cause cardiovascular toxicities, requiring better understanding of their characteristics and associated risk factors.
This review highlights the spectrum of ICI-induced cardiotoxicities and emphasizes the need for cardio-oncologists to understand associated risk factors for better patient monitoring.
Newly approved cancer drugs called ICIs have shown remarkable success in improving patient survival rates, but they also have the potential for inflammatory and immune-related side effects, including those affecting the cardiovascular system. Research has been conducted to understand the development of these toxicities and identify risk factors. This review focuses on the characteristics of ICI-induced cardiotoxicity and discusses the reported risk factors. It is important for cardio-oncologists to understand the basic concepts of these drugs to better understand how cardiotoxicities occur. It might be hard to find reports, where all patients treated with ICIs had developed cardiac toxicity, because there could be other existing and variable factors that influence the likelihood or risk of developing cardiotoxicity during treatment. Various clinical parameters have been explored as potential risk factors, and further investigation is needed through large-scale studies.
No takes yet. Share an insight, caveat, or question.
Lessomo et al. (2023) conducted a review in Cancer treated with immune checkpoint inhibitors. Immune checkpoint inhibitors was evaluated. Immune checkpoint inhibitors are associated with rare but potentially severe cardiovascular toxicities, most notably myocarditis, which require early detection and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: